Cart
sales@molnova.com
Trimebutine
CAS No. 39133-31-8
Trimebutine( —— )
Catalog No. M14347 CAS No. 39133-31-8
Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 27 | In Stock |
|
| 500MG | 37 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTrimebutine
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.
-
DescriptionTrimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetOpioid Receptor
-
RecptorOpioid Receptor
-
Research AreaMetabolic Disease
-
Indication——
Chemical Information
-
CAS Number39133-31-8
-
Formula Weight387.47
-
Molecular FormulaC22H29NO5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 50 mg/mL (129.04 mM)
-
SMILESCCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Prescrire Int. 2013 Oct;22(142):241-2.
molnova catalog
related products
-
Gluten Exorphin C
Gluten exorphin C is an opioid peptide derived from wheat gluten. Its IC50 values are 40 μM and 13.5 μM for μ opioid and δ opioid activities in the GPI and MVD assays, respectively.Gluten Exorphin C, isolated from the pepsin-trypsin-chymotrypsin digest of wheat gluten, was considered as a δ-opioid receptor-selective ligand.Gluten exorphin C, a novel opioid peptide, is isolated from the pepsin-trypsin-chymotrypsin digest of wheat gluten.
-
Noscapine hydrochlor...
A naturally occurring opium alkaloid that is a centrally acting antitussive agent.
-
TAK-285
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
